180 related articles for article (PubMed ID: 38026304)
1. The reimbursement decision speed for oncology new drugs in China and its determinant factors.
Zhu X; Chen Y
Front Public Health; 2023; 11():1207739. PubMed ID: 38026304
[TBL] [Abstract][Full Text] [Related]
2. Policy Updates on Access to and Affordability of Innovative Medicines in China.
Liu GG; Wu J; He X; Jiang Y
Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
[TBL] [Abstract][Full Text] [Related]
3. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
4. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
Pham C; Le K; Draves M; Seoane-Vazquez E
JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
[TBL] [Abstract][Full Text] [Related]
5. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
6. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
7. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
8. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
9. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
10. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
11. Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.
Macabeo B; Wilson L; Xuan J; Guo R; Atanasov P; Zheng L; François C; Laramée P
J Mark Access Health Policy; 2023; 11(1):2218633. PubMed ID: 37325810
[TBL] [Abstract][Full Text] [Related]
12. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
13. New Drug Reimbursement and Pricing Policy in Taiwan.
Chen GT; Chang SC; Chang CJ
Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
[TBL] [Abstract][Full Text] [Related]
14. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
Lau C; Dranitsaris G
Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
[TBL] [Abstract][Full Text] [Related]
16. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
[No Abstract] [Full Text] [Related]
17. [Duration of the Reimbursement Process in Spain for Innovative Drugs Approved by the European Medicines Agency during the Period 2008-2013].
Pinyol C; Valmaseda A; Gómez-Ulloa D; Solozabal M; Restovic G
Rev Esp Salud Publica; 2015 Apr; 89(2):189-200. PubMed ID: 26121628
[TBL] [Abstract][Full Text] [Related]
18. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
Zhou J; Lu H; Pan J
Int J Health Policy Manag; 2024 Mar; ():. PubMed ID: 38618837
[TBL] [Abstract][Full Text] [Related]
19. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
Rawson NSB; Stewart DJ
Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
[TBL] [Abstract][Full Text] [Related]
20. Bridging the new drug access gap between China and the United States and its related policies.
Zhu X; Chen Y
Front Pharmacol; 2023; 14():1296737. PubMed ID: 38259295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
